MicroTransponder key facts
as of Oct 2026- Developer of an implantable neurostimulation device designed to aid stroke recovery and other neurological disorders.
- MicroTransponder is valued at approximately $225.0M as of Oct 2026, set at its later-stage round, Mar 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $207.3M across 9 recorded rounds; the latest was Early Stage VC ($32.5M) in Mar 2025.
- Notable investors include MedTech Innovator, Osage University Partners, Revelation Partners, Gilde Healthcare, Longitude Capital — 18 tracked in total.
- MicroTransponder has filed 13 Form Ds with the SEC since 2010, most recently Mar 2025 ($32.5M sold to 19 investors).
- Status: In IPO Registration.
Valued at $225.0M at its later-stage round, Mar 2025. Nothing has traded since.
- ·The complete investor list: 18 names
- ·Watch MicroTransponder: the Monday email on marks, rounds and moves
MicroTransponder funding rounds
9 roundsWho backs MicroTransponder
18+MicroTransponder valuation
MicroTransponder was valued at $225 million at its later-stage round in Mar 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has MicroTransponder raised?
MicroTransponder has raised $207 million across 9 recorded rounds since 2012. The largest was a $6 million debt round in Jun 2021; the most recent was a $32.5 million early-stage round in Mar 2025.
MicroTransponder has filed 13 Form Ds with the SEC since 2010, most recently in Mar 2025 ($32.5 million sold to 19 investors).
MicroTransponder investors
18 investors are on record for MicroTransponder, including MedTech Innovator, Osage University Partners, Revelation Partners and Gilde Healthcare. By type, the record holds 3 venture capital firms, 1 private equity firm and 1 growth equity firm. The early-stage round in Mar 2025 drew 19 investors.
About MicroTransponder
Developer of an implantable neurostimulation device designed to aid stroke recovery and other neurological disorders. The company's device incorporates paired vagus nerve stimulation and wireless technology to deliver targeted electrical impulses, enhancing neuroplasticity and restoring motor function in post-stroke patients, enabling healthcare practitioners to improve patient outcomes.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2007
- Employees
- 191
- Website
- mobia.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.